Cardiac dysfunction associated with trastuzumab

被引:36
|
作者
Smith, Karen Lisa [1 ]
Dang, Chau [1 ]
Seidman, Andrew D. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Canc Med Serv, New York, NY 10021 USA
关键词
breast cancer; cardiac toxicity; trastuzumab;
D O I
10.1517/14740338.5.5.619
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The HER21neu gene is amplified in similar to 25% of breast cancers, leading to HER2 protein overexpression and shortened overall survival and time to relapse. Trastuzumab is a humanised, monoclonal antibody against HER2, which improves survival for women with metastatic HER2-overexpressing breast cancer and reduces the risk of recurrence in women with early stage HER2-overexpressing breast cancer. Cardiac toxicity was an unexpected finding in the pivotal Phase III trial leading to the approval of trastuzumab, and prospective cardiac monitoring has, therefore, been incorporated into more recent clinical trials of trastuzumab. This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity.
引用
收藏
页码:619 / 629
页数:11
相关论文
共 50 条
  • [1] Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer
    Tham, YL
    Verani, MS
    Chang, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (02) : 131 - 134
  • [2] Reversible and Irreversible Cardiac Dysfunction Associated with Trastuzumab in Breast Cancer
    Yee-Lu Tham
    Mario S Verani
    Jenny Chang
    Breast Cancer Research and Treatment, 2002, 74 : 131 - 134
  • [3] Cardiac dysfunction induced by trastuzumab
    Campone, M
    Bourbouloux, E
    Fumoleau, P
    BULLETIN DU CANCER, 2004, 91 : S166 - S173
  • [5] Management of Trastuzumab-Related Cardiac Dysfunction
    Carver, Joseph R.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2010, 53 (02) : 130 - 139
  • [6] Trastuzumab-Related Cardiac Dysfunction
    Telli, Melinda L.
    Witteles, Ronald M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (02): : 243 - 249
  • [7] Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction
    Beer, Lynn A.
    Kossenkov, Andrew V.
    Liu, Qin
    Prak, Eline Luning
    Domchek, Susan
    Speicher, David W.
    Ky, Bonnie
    CIRCULATION RESEARCH, 2016, 119 (10) : 1135 - 1144
  • [8] Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis
    Chen, Tao
    Xu, Tao
    Li, Yang
    Liang, Chun
    Chen, Juxiang
    Lu, Yicheng
    Wu, Zonggui
    Wu, Shenhong
    CANCER TREATMENT REVIEWS, 2011, 37 (04) : 312 - 320
  • [9] Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect
    Karaca, Mustafa
    Kocoglu, Hakan
    Bilgetekin, Irem
    Ozet, Ahmet
    Sahinli, Hayriye
    Demir, Hacer
    Kankoc, Aykut
    Tural, Deniz
    Yucel, Orhan Kemal
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S536 - S537
  • [10] Is there a window of opportunity to optimize trastuzumab cardiac monitoring?
    Rala de Paula, Bruno Henrique
    Costa, Maria Eduarda Teixeira Ferro
    de Sousa, Carlos Augusto Moreira
    Bines, Jose
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (07): : 403 - 410